中国基金报·2025-06-24 04:25Core Viewpoint - The article discusses the ongoing dispute between two major players in the beauty industry, Juzi Biotechnology and Huaxi Biotechnology, focusing on Juzi's acknowledgment of limitations in their collagen product standards and their plans for improvement [2][8]. Group 1: Juzi Biotechnology's Response - Juzi Biotechnology admitted that their current quality standards, testing methods, and labeling have limitations that do not fully meet the high standards and requirements of industry development and technological advancement [2][8]. - The company plans to collaborate with research institutions to accelerate the optimization and validation of qualitative and quantitative testing methods for recombinant collagen in cosmetics [8]. - Juzi will gradually disclose key technical parameters and quality control data for raw materials and finished products to empower industry development and accept public supervision [8]. Group 2: Industry Standards and Developments - The latest industry standard for recombinant collagen dressings, YY/T 1947-2025, is set to be implemented in March 2026, indicating a need for updated compliance among companies [6]. - Juzi Biotechnology emphasized the necessity for continuous optimization and iteration of their quality standards and methods in response to the rapid development of the recombinant collagen industry and increasing consumer quality demands [8]. Group 3: Huaxi Biotechnology's Position - Huaxi Biotechnology previously addressed concerns regarding the lack of relevant testing standards in the recombinant collagen field, highlighting the misuse of the term "collagen" in the market [9]. - They criticized the misleading use of the term "collagen" by some companies, which do not produce the actual collagen sequence and structure, thus lacking physiological functionality [9]. - Huaxi believes that clear and scientifically verifiable conclusions are essential to avoid prolonged disputes and help companies resolve their issues quickly [9].